Derma Sciences raises $29M, as CEO claims diabetic foot ulcer agent could be global $900M drug
This article was originally published in Scrip
Executive Summary
Derma Sciences has raised about $29 million through the sale of about 3.5 million shares and warrants in a private placement with 18 institutional investors, with part of the funds to be used for advancing its investigational diabetic foot ulcer drug, DSC127, into a Phase III trial that it plans to begin during the first half of 2012. The company also markets wound care products.